213 results on '"Amoroso, Domenico"'
Search Results
2. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
3. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
4. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
5. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study
6. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
7. Abstract PD8-03: Beta blockers and/or ACE inhibitors as cardioprotective strategy for patients affected by nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy (SAFE - NCT02236806): final results of a randomized trial
8. Abstract P3-05-45: Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy
9. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab.
10. Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
11. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab
12. Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non–Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)
13. Bayesian radiocarbon modeling and the absolute chronology of the Middle Bronze Age Thapsos facies in mainland Sicily: a view from St. Ippolito (Caltagirone)
14. Abstract PD5-02: Cardioprotective strategy for non-metastatic breast cancer patients receiving an anthracycline-based chemotherapy: subgroup analysis focused on impact of postoperative breast radiation therapy of the preplanned interim analysis of the phase 3 SAFE trial (NCT2236806)
15. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
16. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy
17. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
18. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy
19. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab
20. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
21. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
22. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients
23. Abstract P5-14-24: Interim analysis of the SAFE trial (NCT2236806): A randomized phase 3 study evaluating a cardiovascular disease prevention strategy using beta-blockers and/or ACE inhibitors in non-metastatic breast cancer patients treated with anthracyclines
24. Loss of nuclear p27kip1 and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma
25. Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy
26. Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine-2 treatment
27. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α
28. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status
29. Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: Results of a multicentric phase II trial
30. Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
31. Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer
32. Chemotherapy versus Tamoxifen versus Chemotherapy plus Tamoxifen. Results of the GROCTA Trial
33. Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
34. Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity
35. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
36. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
37. Scelte terapeutiche e trattamento con sorafenib nell'epatocarcinoma: Analisi finale dello studio GIDEON in Italia
38. FP690SAFETY OF CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG CANCER IN CHRONIC HEMODIALYTIC PATIENTS
39. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
40. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study
41. FOLFOX4/XELOX in stage II–III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial
42. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
43. First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey
44. Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.
45. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
46. Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.
47. Phase II, multicentre, open label, non randomized trial on safety of first line chemotherapy with oral metronomic vinorelbine in the elderly subgroup of NSCLC patients.
48. DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.
49. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
50. Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.